cantab pharmaceuticals the biotechnology company has begun a new round of trials for its kidney transplant drug writes daniel green the trials are the first placebo-controlled in phase ii which is designed to assess how well the drug works if they go well it would be put through the much larger phase iii trials before approval and product launch in 1997 the drug is being developed with baxter international the us healthcare company the drug code-named lm-cd45 is designed to reduce the chance of a newly transplanted kidney being rejected by the patient lm-cd45 holds the promise of reducing the frequency of acute rejection thereby improving the success rate and cost-effectiveness of the transplant procedure said mr don joseph president of baxter's renal division mr paul haycock chief executive said the company was investigating the use of the drug to prevent rejection in transplants of other organs